Patenting AI Discoveries in Life Sciences: Overcoming Eligibility, Disclosure, and Inventorship Challenges

Authors

Dhohyung Kim, Taft, Stettinius & Hollister LLPFollow
Ryan P. Hiler, Taft, Stettinius & Hollister LLPFollow

Document Type

Article

Publication Date

2026

Publication Citation

15 IP Theory, no. 2, 2026, at 19.

Abstract

The pharmaceutical and biotechnology industries face transformative opportunities through artificial intelligence and machine learning integration. However, these technological advances create distinct patent law complications that traditional drug development does not encounter. This article analyzes three interconnected obstacles: establishing eligible subject matter under 35 U.S.C. § 101, meeting disclosure standards under § 112(a), and determining proper inventorship when AI systems contribute substantially to claimed inventions. Drawing from recent USPTO guidance and Federal Circuit precedent, this analysis offers evidence-based strategies for patent practitioners, research scientists, and business leaders seeking robust intellectual property protection for AI-integrated pharmaceutical innovations.

Recommended Citation

Kim, Dhohyung and Hiler, Ryan P. (2026) "Patenting AI Discoveries in Life Sciences: Overcoming Eligibility, Disclosure, and Inventorship Challenges," IP Theory: Vol. 15: Iss. 2, Article 2.
Available at: https://www.repository.law.indiana.edu/ipt/vol15/iss2/2